High-throughput tissue processing for clearer 3D images of lung and colorectal cancers
Validation of a High-Throughput, Large-Format, Tissue-Specific Preprocessing Protocol for Lung and Colorectal Cancer
This project tests a high-throughput tissue-processing and 3D imaging approach to create more detailed tumor images from people with lung or colorectal cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Sex | All |
| Sponsor | Nanfang Hospital, Southern Medical University Academic / other |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT07239063 on ClinicalTrials.gov |
What this trial studies
This observational project will apply a large-format, high-throughput tissue preprocessing system together with three-dimensional imaging to lung and colorectal cancer specimens. Investigators will optimize tissue-clearing workflows and establish transparency and quality criteria tailored to these tumor types. They will develop and validate an iterative 3D immunofluorescent staining protocol to produce high-resolution, morphologically complete datasets. The generated datasets will be used to characterize spatial tumor architecture and to support future prospective validation of imaging-derived markers.
Who should consider this trial
Good fit: Ideal candidates are people with a pathological diagnosis of lung or colorectal cancer who have complete clinical data and available tumor materials such as H&E slides, paraffin blocks, or discarded ex vivo specimens.
Not a fit: Patients without available or quality-controlled tissue specimens or those whose care does not depend on tissue-based spatial imaging are unlikely to receive direct benefit from participation.
Why it matters
Potential benefit: If successful, the method could produce much more detailed maps of tumor structure that help researchers and clinicians find more precise treatment targets and potentially improve patient outcomes.
How similar studies have performed: Related tissue-clearing and 3D imaging techniques have shown promising results in research settings, but large-scale clinical validation specifically for lung and colorectal cancer specimens is still limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients who have been pathologically diagnosed as having lung cancer or colorectal cancer. 2. Patients with complete clinical data and tumor tissue materials, including H\&E slides, paraffin blocks, and discarded ex vivo specimens. Exclusion Criteria: 1.Patients with missing data or specimens not meeting quality control requirements for analysis.
Where this trial is running
Guangzhou, Guangdong
- Nanfang Hospital, Southern Medical University — Guangzhou, Guangdong, China (Recruiting)
Study contacts
- Study coordinator: Zhengyu Zhang
- Email: zzyusmu@163.com
- Phone: +8613837365993
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.